Eupraxia Pharmaceuticals Files 6-K Report
Ticker: EPRX · Form: 6-K · Filed: Jun 5, 2024 · CIK: 1581178
Sentiment: neutral
Topics: filing, press-release
TL;DR
Eupraxia Pharmaceuticals filed a 6-K on June 5th, including a press release. Check for updates.
AI Summary
Eupraxia Pharmaceuticals Inc. filed a Form 6-K on June 5, 2024, reporting information as of that date. The filing includes Exhibit 99.1, which is a press release dated June 5, 2024. The company is incorporated in Canada and its principal executive offices are located in Victoria, British Columbia.
Why It Matters
This filing provides updated information and potentially material disclosures from Eupraxia Pharmaceuticals Inc. to investors and the market.
Risk Assessment
Risk Level: low — This is a routine filing (6-K) that primarily serves to submit a press release and does not appear to contain significant new financial or operational disclosures.
Key Players & Entities
- Eupraxia Pharmaceuticals Inc. (company) — Registrant
- June 5, 2024 (date) — Filing date and press release date
- Bruce Cousins (person) — Signatory for the filing
- Victoria, British Columbia, Canada (location) — Location of principal executive offices
FAQ
What is the primary purpose of this 6-K filing?
The primary purpose of this 6-K filing is to report information as of June 5, 2024, and to include Exhibit 99.1, which is a press release dated June 5, 2024.
What is the filing date of this report?
The filing date of this report is June 5, 2024.
Where are Eupraxia Pharmaceuticals Inc.'s principal executive offices located?
Eupraxia Pharmaceuticals Inc.'s principal executive offices are located at 201-2067 Cadboro Bay Road, Victoria, British Columbia, Canada V8R 5G4.
Who signed this report on behalf of Eupraxia Pharmaceuticals Inc.?
Bruce Cousins signed this report on behalf of Eupraxia Pharmaceuticals Inc.
What exhibit is included as part of this 6-K report?
Exhibit 99.1, a Press Release dated June 5, 2024, is included as part of this report.
Filing Stats: 169 words · 1 min read · ~1 pages · Grade level 14.2 · Accepted 2024-06-05 07:01:47
Filing Documents
- form6k.htm (6-K) — 11KB
- ex991.htm (EX-99.1) — 14KB
- logo.jpg (GRAPHIC) — 23KB
- 0001279569-24-000699.txt ( ) — 58KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Eupraxia Pharmaceuticals Inc. Date: June 5, 2024 By: /s/ Bruce Cousins Name: Bruce Cousins Title: President and Chief Financial Officer